Sept. 21 showed exactly where the weight-loss drug race stands. Eli Lilly (LLY) CEO Dave Ricks told CNBC that about 700,000 seniors have started weight-loss drugs since Medicare began covering them in July, and roughly 70% chose Lilly. On the same day, Novo Nordisk (NVO) held its investor day in London. CEO Mike Doustdar confirmed that Wegovy and Ozempic will lose their exclusive rights in the early 2030s, opening the door to cheaper copies. Novo’s U.S. shares fell nearly 8% in a single trading session.